Skincare Mondays | Colloidal Oatmeal: Composition, Benefits & Mechanism of Action
Colloidal OatmealColloidal oatmeal has a long history of use in the treatment of dermatologic disease. Oat is composed of various phytochemicals which contribute to its wide-ranging function and clinical use in atopic dermatitis and other skin conditions resulting from an impaired skin barrier and inflammation. OAT COMPOSITION & BENEFITS The main components of colloidal oatmeal are polysaccharides (including …
Colloidal Oatmeal
Top Three Social Media No-Nos for Dermatologists
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic and Surgical Conference, interviewed Dr. DiAnne Davis (a board-certified cosmetic dermatologist specializing in noninvasive facial rejuvenation, skin of color, hair loss, and cosmetic dermatologic surgery) about social media dos and don'ts. Watch as she offers her three best tips on how dermatologists should protect themselves bef …
Pop Quiz #182
The correct answer is A. Ruxolitinib The photo depicts a patient with Alopecia Areata. The FDA approved Baricitinib, a JAK 1/2 inhibitor, in June 2022 for the treatment of alopecia areata. Baricitinib blocks JAK 1/2, just as Ruxolitinib, which was FDA approved for the treatment of atopic dermatitis in September 2021. Abrocitinib, while a JAK inhibitor, only inhibits JAK1 as opposed to …
Tralokinumab-ldrm Therapeutic Cheat Sheet
tralokinumabAtopic dermatitis is a common, chronic, life-altering disease. With its visibility and debilitating pruritus, atopic dermatitis significantly impacts our patients’ quality of life. For those with resistant and extensive disease, we are happy to have numerous new systemic agents at our disposal, one being tralokinumab, an IL-13 antagonist. We continue our series, Therapeutic Cheat Sheet, with a c …
tralokinumab
Key Tips for Dermatologists in Prescribing and Managing JAK Inhibitors
JAK InhibitorsNext Steps in Derm, in partnership with ODAC Dermatology, Aesthetic and Surgical Conference, interviewed Dr. Neal Bhatia (a board-certified Dermatologist who serves as Director of Clinical Dermatology at Therapeutics Clinical Research ) about the latest with JAK inhibitors. Watch as he summarizes the most recent trials, approvals, and developments. Plus why doctors shouldn't be afraid to dive in w …
JAK Inhibitors
error

Enjoy this blog? Please spread the word :)